Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab (SHR-1316) Perioperative Treatment in Resectable NSCLC
NCT04316364Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Jul 2020; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04316364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316364.